|
1.
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Saal LH, Johansson P, Holm K, et al: Poor
prognosis in carcinoma is associated with a gene expression
signature of aberrant PTEN tumor suppressor pathway activity. Proc
Natl Acad Sci USA. 104:7564–7569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Aleskandarany MA, Rakha EA, Ahmed MA, et
al: PIK3CA expression in invasive breast cancer: a biomarker of
poor prognosis. Breast Cancer Res Treat. 122:45–53. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kato S, Iida S, Higuchi T, et al: PIK3CA
mutation is predictive of poor survival in patients with colorectal
cancer. Int J Cancer. 121:1771–1778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chapuis N, Tamburini J, Cornillet-Lefebvre
P, et al: Autocrine IGF-1/IGF-1R signaling is responsible for
constitutive PI3K/Akt activation in acute myeloid leukemia:
therapeutic value of neutralizing anti-IGF-1R antibody.
Haematologica. 95:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Muders MH, Zhang H, Wang E, Tindall DJ and
Datta K: Vascular endothelial growth factor-C protects prostate
cancer cells from oxidative stress by the activation of mammalian
target of rapamycin complex-2 and AKT-1. Cancer Res. 69:6042–6048.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Puri N and Salgia R: Synergism of EGFR and
c-Met pathways, cross-talk and inhibition, in non-small cell lung
cancer. J Carcinog. 7:92008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
De Preter K, Vandesompele J, Heimann P, et
al: Human fetal neuroblast and neuroblastoma transcriptome analysis
confirms neuroblast origin and highlights neuroblastoma candidate
genes. Genome Biol. 7:R842006.
|
|
10.
|
Dam V, Morgan BT, Mazanek P and Hogarty
MD: Mutations in PIK3CA are infrequent in neuroblastoma. BMC
Cancer. 6:1772006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Moritake H, Horii Y, Kuroda H and Sugimoto
T: Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Genet
Cytogenet. 125:151–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Caren H, Fransson S, Ejeskar K, Kogner P
and Martinsson T: Genetic and epigenetic changes in the common 1p36
deletion in neuroblastoma tumours. Br J Cancer. 97:1416–1424. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Boller D, Schramm A, Doepfner KT, et al:
Targeting the phosphoinositide 3-kinase isoform p110delta impairs
growth and survival in neuroblastoma cells. Clin Cancer Res.
14:1172–1181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Fransson S, Martinsson T and Ejeskar K:
Neuroblastoma tumors with favorable and unfavorable outcomes:
significant differences in mRNA expression of genes mapped at
1p36.2. Genes Chromosomes Cancer. 46:45–52. 2007. View Article : Google Scholar
|
|
15.
|
Johnsen JI, Segerstrom L, Orrego A, et al:
Inhibitors of mammalian target of rapamycin downregulate MYCN
protein expression and inhibit neuroblastoma growth in vitro and in
vivo. Oncogene. 27:2910–2922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Opel D, Poremba C, Simon T, Debatin KM and
Fulda S: Activation of Akt predicts poor outcome in neuroblastoma.
Cancer Res. 67:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Brodeur GM, Minturn JE, Ho R, et al: Trk
receptor expression and inhibition in neuroblastomas. Clin Cancer
Res. 15:3244–3250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Fredlund E, Ringner M, Maris JM and
Pahlman S: High Myc pathway activity and low stage of neuronal
differentiation associate with poor outcome in neuroblastoma. Proc
Natl Acad Sci USA. 105:14094–14099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hedborg F, Bjelfman C, Sparen P, Sandstedt
B and Pahlman S: Biochemical evidence for a mature phenotype in
morphologically poorly differentiated neuroblastomas with a
favourable outcome. Eur J Cancer. 31A:435–443. 1995. View Article : Google Scholar
|
|
20.
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Chesler L, Schlieve C, Goldenberg DD, et
al: Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn
protein and blocks malignant progression in neuroblastoma. Cancer
Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yamamoto M, Acevedo-Duncan M, Chalfant CE,
Patel NA, Watson JE and Cooper DR: The roles of protein kinase C
beta I and beta II in vascular smooth muscle cell proliferation.
Exp Cell Res. 240:349–358. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Borner C, Ueffing M, Jaken S, Parker PJ
and Weinstein IB: Two closely related isoforms of protein kinase C
produce reciprocal effects on the growth of rat fibroblasts.
Possible molecular mechanisms J Biol Chem. 270:78–86.
1995.PubMed/NCBI
|
|
24.
|
Zeidman R, Pettersson L, Sailaja PR, et
al: Novel and classical protein kinase C isoforms have different
functions in proliferation, survival and differentiation of
neuroblastoma cells. Int J Cancer. 81:494–501. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Svensson K, Zeidman R, Troller U, Schultz
A and Larsson C: Protein kinase C beta1 is implicated in the
regulation of neuroblastoma cell growth and proliferation. Cell
Growth Differ. 11:641–648. 2000.PubMed/NCBI
|
|
26.
|
Mak NK, Lung HL, Wong RN, Leung HW, Tsang
HY and Leung KN: Expression of protein kinase C isoforms in
euxanthone-induced differentiation of neuroblastoma cells. Planta
Med. 67:400–405. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Macfarlane DE and Manzel L: Activation of
beta-isozyme of protein kinase C (PKC beta) is necessary and
sufficient for phorbol ester-induced differentiation of HL-60
promyelocytes. Studies with PKC beta-defective PET mutant J Biol
Chem. 269:4327–4331. 1994.PubMed/NCBI
|
|
28.
|
Liu YF, Paz K, Herschkovitz A, et al:
Insulin stimulates PKCzeta-mediated phosphorylation of insulin
receptor substrate-1 (IRS-1). A self-attenuated mechanism to
negatively regulate the function of IRS proteins. J Biol Chem.
276:14459–14465. 2001.
|
|
29.
|
Nazarenko I, Jenny M, Keil J, et al:
Atypical protein kinase C zeta exhibits a proapoptotic function in
ovarian cancer. Mol Cancer Res. 8:919–934. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Guo H, Gu F, Li W, et al: Reduction of
protein kinase C zeta inhibits migration and invasion of human
glioblastoma cells. J Neurochem. 109:203–213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Mei Y, Wang Z, Zhang L, et al: Regulation
of neuroblastoma differentiation by forkhead transcription factors
FOXO1/3/4 through the receptor tyrosine kinase PDGFRA. Proc Natl
Acad Sci USA. 109:4898–4903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Pahlman S, Johansson I, Westermark B and
Nister M: Platelet-derived growth factor potentiates phorbol
ester-induced neuronal differentiation of human neuroblastoma
cells. Cell Growth Differ. 3:783–790. 1992.
|
|
33.
|
Yu J, Ustach C and Kim HR:
Platelet-derived growth factor signaling and human cancer. J
Biochem Mol Biol. 36:49–59. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Barber DF, Alvarado-Kristensson M,
Gonzalez-Garcia A, Pulido R and Carrera AC: PTEN regulation, a
novel function for the p85 subunit of phosphoinositide 3-kinase.
Sci STKE. 2006.pe492006.PubMed/NCBI
|
|
35.
|
Rabinovsky R, Pochanard P, McNear C, et
al: p85 associates with unphosphorylated PTEN and the
PTEN-associated complex. Mol Cell Biol. 29:5377–5388. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Chagpar RB, Links PH, Pastor MC, et al:
Direct positive regulation of PTEN by the p85 subunit of
phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA.
107:5471–5476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Taniguchi CM, Winnay J, Kondo T, et al:
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert
tumor suppressor properties through negative regulation of growth
factor signaling. Cancer Res. 70:5305–5315. 2010. View Article : Google Scholar
|
|
38.
|
Luo J and Cantley LC: The negative
regulation of phosphoinositide 3-kinase signaling by p85 and it’s
implication in cancer. Cell Cycle. 4:1309–1312. 2005.
|
|
39.
|
Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic
T, Orr GA and Backer JM: Regulation of the p85/p110
phosphatidylinositol 3’-kinase: stabilization and inhibition of the
p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell
Biol. 18:1379–1387. 1998.
|
|
40.
|
Shekar SC, Wu H, Fu Z, et al: Mechanism of
constitutive phosphoinositide 3-kinase activation by oncogenic
mutants of the p85 regulatory subunit. J Biol Chem.
280:27850–27855. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Jimenez C, Jones DR, Rodriguez-Viciana P,
et al: Identification and characterization of a new oncogene
derived from the regulatory subunit of phosphoinositide 3-kinase.
EMBO J. 17:743–753. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Philp AJ, Campbell IG, Leet C, et al: The
phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in
human ovarian and colon tumors. Cancer Res. 61:7426–7429. 2001.
|
|
43.
|
Lopez-Carballo G, Moreno L, Masia S, Perez
P and Barettino D: Activation of the phosphatidylinositol
3-kinase/Akt signaling pathway by retinoic acid is required for
neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol
Chem. 277:25297–25304. 2002. View Article : Google Scholar
|
|
44.
|
Evangelopoulos ME, Weis J and Kruttgen A:
Signalling pathways leading to neuroblastoma differentiation after
serum withdrawal: HDL blocks neuroblastoma differentiation by
inhibition of EGFR. Oncogene. 24:3309–3318. 2005. View Article : Google Scholar
|
|
45.
|
Evangelopoulos ME, Weis J and Kruttgen A:
Mevastatin-induced neurite outgrowth of neuroblastoma cells via
activation of EGFR. J Neurosci Res. 87:2138–2144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Wilzen A, Nilsson S, Sjoberg RM, Kogner P,
Martinsson T and Abel F: The Phox2 pathway is differentially
expressed in neuroblastoma tumors, but no mutations were found in
the candidate tumor suppressor gene PHOX2A. Int J Oncol.
34:697–705. 2009.
|
